Showing results (1261-1270 of 3,351) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|April 17, 2020
International Valuation Protocol for the EQ-5D-Y-3LJuan M Ramos-Goñi, Mark Oppe, Elly Stolk, et al.Pharmacoeconomics|September 18, 2003
Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapiesChristian Krauth, Noushin Jalilvand, Tobias Welte, et al.Pharmacoeconomics|June 1, 2001
On individual preferences and aggregation in economic evaluation in healthcareB Liljas, B LindgrenPharmacoeconomics|June 1, 2001
Cost-benefit analysis of a Haemophilus influenzae type b meningitis prevention programme in The PhilippinesM R Limcangco, C L Armour, E G Salole, et al.Pharmacoeconomics|June 1, 2001
Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in OnychomycosisR Jansen, W K Redekop, F F RuttenPharmacoeconomics|January 9, 2001
Costs of deep foot infections in patients with diabetes mellitusG R Tennvall, J Apelqvist, M EnerothPharmacoeconomics|January 9, 2001
Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthmaR J Ozminkowski, S Wang, W D Marder, et al.Pharmacoeconomics|March 22, 2003
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)Dean G Smith, Christopher R McBurneyPharmacoeconomics|May 20, 2003
Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in GermanyChrista Claes, Johann-Matthias Graf von der SchulenburgPharmacoeconomics|June 17, 2003
Assessing the economic impact of adverse drug effectsRosa Rodríguez-Monguió, María José Otero, Joan RoviraPageof 336